<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628549</url>
  </required_header>
  <id_info>
    <org_study_id>PR-10411</org_study_id>
    <nct_id>NCT01628549</nct_id>
  </id_info>
  <brief_title>Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris</brief_title>
  <official_title>A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of a Novel Tetracycline Compared to Placebo in the Treatment of Facial Acne Vulgaris, Study PR-10411</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo
      for the treatment of moderate to severe facial acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2012</start_date>
  <completion_date type="Actual">January 31, 2013</completion_date>
  <primary_completion_date type="Actual">November 16, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Up to Week 12)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Dichotomized IGA (Investigator Global Assessment) Score at Final Visit</measure>
    <time_frame>Final Visit (Up to Week 12)</time_frame>
    <description>The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4.
The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Absolute Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12 and the Final Visit</measure>
    <time_frame>Baseline (Week 0) up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Absolute Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</measure>
    <time_frame>Baseline (Week 0) up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</measure>
    <time_frame>Baseline (Week 0) up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</measure>
    <time_frame>Baseline (Week 0) up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Dichotomized IGA Score at Weeks 1, 2, 4, 8, and 12</measure>
    <time_frame>Baseline to Final Visit (Up to Week 12)</time_frame>
    <description>The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4.
The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>P005672-HCl approximately 0.75 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P005672-HCl approximately 1.5 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P005672-HCl approximately 3.0 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg P005672-HCl</intervention_name>
    <description>P005672-HCl administered as an oral capsule(s) once daily</description>
    <arm_group_label>P005672-HCl approximately 0.75 mg/kg/day</arm_group_label>
    <arm_group_label>P005672-HCl approximately 1.5 mg/kg/day</arm_group_label>
    <other_name>WC3035, Sarecycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose-matched Placebo capsule administered as an oral capsule(s) once daily</description>
    <arm_group_label>P005672-HCl approximately 0.75 mg/kg/day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg P005672-HCl</intervention_name>
    <description>P005672-HCl administered as an oral capsule(s) once daily</description>
    <arm_group_label>P005672-HCl approximately 3.0 mg/kg/day</arm_group_label>
    <other_name>WC3035, Sarecycline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  if women of child-bearing potential, have a negative urine pregnancy test

          -  Willing to use only a non-medicated cleanser and to refrain from use of any other acne
             medication, medicated cleanser, excessive sun exposure, and tanning booths for the
             duration of the study

          -  Male or female, 12-45 years of age with body weight between 52 and 88 kg

          -  Diagnosis of acne vulgaris with:

             20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100
             noninflammatory lesions (open and closed comedones)

          -  No more than 2 nodules on the face

          -  Investigator's Global Assessment (IGA) score of moderate (3) to severe (4)

        Exclusion Criteria:

          -  Dermatological condition of face or facial hair that could interfere with clinical
             evaluations subjects who have used the following medications (topical refers only to
             the facial area) will not be eligible:

        Within 1 week prior to randomization:

          -  Medicated facial cleansers

          -  Topical acne treatments (other than those listed below)

        Within 4 weeks prior to randomization:

          -  Topical retinoids

          -  Topical anti-inflammatories and corticosteroids

          -  Systemic antibiotics

          -  Systemic acne treatments

        Within 12 weeks prior to randomization:

          -  Systemic retinoids

          -  Systemic corticosteroids

          -  Pseudomembranous colitis or antibiotic-associated colitis

          -  Hepatitis, liver damage or renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herman Ellman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Warner Chilcott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Granger</city>
        <state>Indiana</state>
        <zip>46530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>44532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <results_first_submitted>December 18, 2018</results_first_submitted>
  <results_first_submitted_qc>December 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <disposition_first_submitted>December 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>December 11, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 13, 2014</disposition_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarecycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
        </group>
        <group group_id="P2">
          <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
          <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
        </group>
        <group group_id="P3">
          <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
          <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
        </group>
        <group group_id="P4">
          <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
          <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrawn for noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>abnormal laboratory test results</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>positive pregnancy test</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>285 participants were randomized to double-blind treatment (Safety population)</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
        </group>
        <group group_id="B2">
          <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
          <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
        </group>
        <group group_id="B3">
          <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
          <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
        </group>
        <group group_id="B4">
          <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
          <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="66"/>
            <count group_id="B5" value="285"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="6.99"/>
                    <measurement group_id="B2" value="19.7" spread="5.92"/>
                    <measurement group_id="B3" value="19.9" spread="7.04"/>
                    <measurement group_id="B4" value="20.3" spread="7.11"/>
                    <measurement group_id="B5" value="20.2" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Five subjects in the Safety Population checked multiple races.</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.80" spread="10.436"/>
                    <measurement group_id="B2" value="167.49" spread="9.047"/>
                    <measurement group_id="B3" value="167.23" spread="7.380"/>
                    <measurement group_id="B4" value="167.33" spread="9.764"/>
                    <measurement group_id="B5" value="166.96" spread="9.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at Baseline</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.47" spread="10.306"/>
                    <measurement group_id="B2" value="66.37" spread="8.749"/>
                    <measurement group_id="B3" value="69.69" spread="11.861"/>
                    <measurement group_id="B4" value="67.31" spread="9.486"/>
                    <measurement group_id="B5" value="67.94" spread="10.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit</title>
        <time_frame>Baseline (Week 0) to Final Visit (Up to Week 12)</time_frame>
        <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
          </group>
          <group group_id="O2">
            <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
            <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
          </group>
          <group group_id="O3">
            <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
            <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
          </group>
          <group group_id="O4">
            <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
            <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit</title>
          <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population.</population>
          <units>Number of Inflammatory Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="14.18"/>
                    <measurement group_id="O2" value="14.4" spread="13.01"/>
                    <measurement group_id="O3" value="17.6" spread="16.65"/>
                    <measurement group_id="O4" value="17.1" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4344</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>5.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0266</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>4.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>8.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0317</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>4.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>8.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Dichotomized IGA (Investigator Global Assessment) Score at Final Visit</title>
        <description>The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4.
The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.</description>
        <time_frame>Final Visit (Up to Week 12)</time_frame>
        <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
          </group>
          <group group_id="O2">
            <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
            <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
          </group>
          <group group_id="O3">
            <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
            <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
          </group>
          <group group_id="O4">
            <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
            <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>The Dichotomized IGA (Investigator Global Assessment) Score at Final Visit</title>
          <description>The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4.
The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.</description>
          <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3300</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference vs placebo in success rate</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.82</ci_lower_limit>
            <ci_upper_limit>14.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0159</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference vs placebo in success rate</param_type>
            <param_value>13.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>25.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4834</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference vs placebo in success rate</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.44</ci_lower_limit>
            <ci_upper_limit>15.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Absolute Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12 and the Final Visit</title>
        <time_frame>Baseline (Week 0) up to Week 12</time_frame>
        <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
          </group>
          <group group_id="O2">
            <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
            <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
          </group>
          <group group_id="O3">
            <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
            <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
          </group>
          <group group_id="O4">
            <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
            <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>The Absolute Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12 and the Final Visit</title>
          <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
          <units>Count of Inflammatory Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="9.07"/>
                    <measurement group_id="O2" value="5.4" spread="9.28"/>
                    <measurement group_id="O3" value="5.4" spread="8.44"/>
                    <measurement group_id="O4" value="5.9" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="10.13"/>
                    <measurement group_id="O2" value="8.5" spread="10.02"/>
                    <measurement group_id="O3" value="8.2" spread="14.45"/>
                    <measurement group_id="O4" value="9.7" spread="11.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="10.04"/>
                    <measurement group_id="O2" value="9.3" spread="13.84"/>
                    <measurement group_id="O3" value="11.7" spread="15.36"/>
                    <measurement group_id="O4" value="12.8" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="12.57"/>
                    <measurement group_id="O2" value="13.1" spread="11.89"/>
                    <measurement group_id="O3" value="15.0" spread="16.66"/>
                    <measurement group_id="O4" value="14.3" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="14.18"/>
                    <measurement group_id="O2" value="14.3" spread="13.00"/>
                    <measurement group_id="O3" value="17.6" spread="16.65"/>
                    <measurement group_id="O4" value="17.1" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Final Visit(Up to Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="14.18"/>
                    <measurement group_id="O2" value="14.4" spread="13.01"/>
                    <measurement group_id="O3" value="17.6" spread="16.65"/>
                    <measurement group_id="O4" value="17.1" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Absolute Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</title>
        <time_frame>Baseline (Week 0) up to Week 12</time_frame>
        <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
          </group>
          <group group_id="O2">
            <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
            <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
          </group>
          <group group_id="O3">
            <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
            <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
          </group>
          <group group_id="O4">
            <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
            <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>The Absolute Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</title>
          <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
          <units>Count of Noninflammatory Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="12.99"/>
                    <measurement group_id="O2" value="3.8" spread="14.28"/>
                    <measurement group_id="O3" value="4.3" spread="14.10"/>
                    <measurement group_id="O4" value="5.1" spread="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="16.02"/>
                    <measurement group_id="O2" value="9.4" spread="13.58"/>
                    <measurement group_id="O3" value="7.8" spread="16.92"/>
                    <measurement group_id="O4" value="7.9" spread="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="24.17"/>
                    <measurement group_id="O2" value="10.0" spread="17.25"/>
                    <measurement group_id="O3" value="9.9" spread="20.58"/>
                    <measurement group_id="O4" value="12.7" spread="15.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="22.52"/>
                    <measurement group_id="O2" value="14.3" spread="21.44"/>
                    <measurement group_id="O3" value="14.0" spread="22.22"/>
                    <measurement group_id="O4" value="15.2" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="21.63"/>
                    <measurement group_id="O2" value="17.9" spread="19.85"/>
                    <measurement group_id="O3" value="19.1" spread="22.33"/>
                    <measurement group_id="O4" value="17.0" spread="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Final Visit(Up to Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="21.63"/>
                    <measurement group_id="O2" value="17.9" spread="19.83"/>
                    <measurement group_id="O3" value="19.1" spread="22.33"/>
                    <measurement group_id="O4" value="17.0" spread="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</title>
        <time_frame>Baseline (Week 0) up to Week 12</time_frame>
        <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
          </group>
          <group group_id="O2">
            <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
            <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
          </group>
          <group group_id="O3">
            <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
            <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
          </group>
          <group group_id="O4">
            <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
            <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change From Baseline in the Inflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</title>
          <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
          <units>Percent Change - Inflammatory Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="27.82"/>
                    <measurement group_id="O2" value="17.2" spread="28.43"/>
                    <measurement group_id="O3" value="17.8" spread="26.39"/>
                    <measurement group_id="O4" value="19.4" spread="26.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="29.02"/>
                    <measurement group_id="O2" value="26.4" spread="32.60"/>
                    <measurement group_id="O3" value="25.8" spread="36.16"/>
                    <measurement group_id="O4" value="30.6" spread="35.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="28.84"/>
                    <measurement group_id="O2" value="29.3" spread="38.90"/>
                    <measurement group_id="O3" value="34.1" spread="35.27"/>
                    <measurement group_id="O4" value="40.0" spread="31.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" spread="35.60"/>
                    <measurement group_id="O2" value="39.8" spread="34.47"/>
                    <measurement group_id="O3" value="44.3" spread="37.99"/>
                    <measurement group_id="O4" value="44.5" spread="37.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" spread="43.00"/>
                    <measurement group_id="O2" value="43.3" spread="39.70"/>
                    <measurement group_id="O3" value="53.6" spread="37.65"/>
                    <measurement group_id="O4" value="53.5" spread="35.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Final Visit(Up to Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" spread="43.00"/>
                    <measurement group_id="O2" value="43.5" spread="39.72"/>
                    <measurement group_id="O3" value="53.6" spread="37.65"/>
                    <measurement group_id="O4" value="53.5" spread="35.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</title>
        <time_frame>Baseline (Week 0) up to Week 12</time_frame>
        <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
          </group>
          <group group_id="O2">
            <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
            <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
          </group>
          <group group_id="O3">
            <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
            <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
          </group>
          <group group_id="O4">
            <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
            <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change From Baseline in the Noninflammatory Lesion Count at Weeks 1, 2, 4, 8, 12, and the Final Visit</title>
          <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
          <units>Percent change - noninflammatory lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="24.07"/>
                    <measurement group_id="O2" value="7.7" spread="26.87"/>
                    <measurement group_id="O3" value="8.3" spread="25.20"/>
                    <measurement group_id="O4" value="10.6" spread="25.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="28.36"/>
                    <measurement group_id="O2" value="16.7" spread="24.99"/>
                    <measurement group_id="O3" value="14.6" spread="30.57"/>
                    <measurement group_id="O4" value="16.0" spread="30.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="37.78"/>
                    <measurement group_id="O2" value="18.3" spread="33.17"/>
                    <measurement group_id="O3" value="19.2" spread="35.60"/>
                    <measurement group_id="O4" value="25.7" spread="29.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="40.69"/>
                    <measurement group_id="O2" value="26.1" spread="38.84"/>
                    <measurement group_id="O3" value="27.5" spread="38.54"/>
                    <measurement group_id="O4" value="30.4" spread="38.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="35.32"/>
                    <measurement group_id="O2" value="34.3" spread="36.40"/>
                    <measurement group_id="O3" value="37.2" spread="38.44"/>
                    <measurement group_id="O4" value="32.8" spread="42.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Final Visit(Up to Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="35.32"/>
                    <measurement group_id="O2" value="34.1" spread="36.28"/>
                    <measurement group_id="O3" value="37.2" spread="38.44"/>
                    <measurement group_id="O4" value="32.8" spread="42.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Dichotomized IGA Score at Weeks 1, 2, 4, 8, and 12</title>
        <description>The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4.
The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.</description>
        <time_frame>Baseline to Final Visit (Up to Week 12)</time_frame>
        <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
          </group>
          <group group_id="O2">
            <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
            <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
          </group>
          <group group_id="O3">
            <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
            <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
          </group>
          <group group_id="O4">
            <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
            <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>The Dichotomized IGA Score at Weeks 1, 2, 4, 8, and 12</title>
          <description>The Investigator Global Assessment Scale (IGA) for Acne Vulgaris Score is a 5-point ordinal scale ranging from 0 to 4.
The dichotomized IGA score, where success was defined as at least a 2-grade decrease in the IGA score during the Final Visit as compared to the Baseline Visit.</description>
          <population>Of the 285 participants in the Safety Population, 284 received a post-Baseline efficacy assessment, to comprise the mITT (Modified Intent-to-Treat) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (Up to Week 12)</title>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Screening (up to week -12) to Week 12 plus 30 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Two placebo capsules matching P005672-HCl, taken orally each day</description>
        </group>
        <group group_id="E2">
          <title>P005672-HCl Approximately 0.75 mg/kg/Day</title>
          <description>One P005672-HCl 50 mg capsule and one Placebo capsule, taken orally each day</description>
        </group>
        <group group_id="E3">
          <title>P005672-HCl Approximately 1.5 mg/kg/Day</title>
          <description>Two P005672-HCl 50 mg capsules, taken orally each day</description>
        </group>
        <group group_id="E4">
          <title>P005672-HCl Approximately 3.0 mg/kg/Day</title>
          <description>Two P005672-HCl 100 mg capsules, taken orally each day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The data obtained in this study are the property of the Sponsor, any manuscript or other presentation of data must first be reviewed by the Sponsor before its submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thearpeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

